

1 **Title: SARS CoV-2 Serosurvey in Addis Ababa, Ethiopia**

2

3 **Short Title: SARS CoV-2 Serosurvey in Addis Ababa, Ethiopia**

4

5 **Authors:** John H. Kempen, MD, MPH, MHS, PhD,¹⁻⁴ Aida Abashawl, MD, MPH, MS,⁵ Hilkiiah
6 Kinfemichael,⁴ Mesfin Nigussie Difabachew, MD,⁶ Christopher J. Kempen,³ Melaku Tesfaye
7 Debele,⁶ Abel A. Menkir,⁴ Maranatha T. Assefa,⁴ Eyob H. Asfaw,⁴ Leul B. Habtegabriel,⁴
8 Yohannes Sitotaw Addisie, BSC, MSC,⁷ Eric J. Nilles, MD, MSC,^{2,8} and Joseph C. Longenecker,
9 MD, MPH, PhD.⁹

10

11 1. Department of Ophthalmology, Massachusetts Eye and Ear and Harvard Medical School;
12 and Schepens Eye Research Institute; Boston, Massachusetts, USA.

13 2. Massachusetts Consortium on Pathogen Readiness (MassCPR), Boston, Massachusetts,
14 USA.

15 3. MyungSung Christian Medical Center (MCM) Eye Unit, MCM General Hospital, Addis
16 Ababa, Ethiopia.

17 4. MyungSung Medical School, Addis Ababa, Ethiopia.

18 5. Berhan Public Health and Eye Care Consultancy, Addis Ababa, Ethiopia.

19 6. International Clinical Laboratories, Addis Ababa, Ethiopia.

20 7. Ethiopian Biotechnology Institute, Addis Ababa, Ethiopia.

21 8. Department of Emergency Medicine, Brigham and Women's Hospital and Harvard
22 Medical School, Boston, Massachusetts, USA.

23 9. Faculty of Public Health and Department of Epidemiology, Faculty of Medicine, Kuwait
24 University, Kuwait City, Kuwait.

25

26 **Word Count:** 793 words

27

28 **Funding:** Laboratory testing in the study was supported by International Clinical Laboratories,
29 Addis Ababa, Ethiopia. Compliance expenses were paid by Massachusetts Eye and Ear, Boston,
30 MA, USA.

31

32 **Financial Disclosures:** John H. Kempen, MD, PhD is a consultant (Data and Safety Monitoring
33 Committee Chair) for Gilead Sciences, Inc.

34

35 **Corresponding Author:** John H. Kempen, M.D., Ph.D.; Address: Department of
36 Ophthalmology, Massachusetts Eye and Ear and Harvard Medical School; Schepens Eye
37 Research Institute, 20 Staniford Street, Boston, MA 02114, USA.

38 Phone: +1 617-573-4494

39 Fax: +1 617-912-0117

40 Email: john_kempen@meei.harvard.edu.

41 ORCID ID: 0000-0002-2967-4792

42

43 The global COVID-19 pandemic caused by SARS CoV-2 is causing both mortality/morbidity
44 and collateral social and economic damage related to public panic and aggressive public policy
45 measures to contain the disease worldwide.(1) The epidemic appears to have taken hold much
46 more slowly in sub-Saharan Africa than most of the world.(2) Antibody testing to evaluate the
47 population proportion previously infected with SARS CoV-2 has the potential to guide public
48 policy, but has not been reported so far for sub-Saharan Africa.

49

50 Because a large proportion of cases of COVID-19 are asymptomatic and because the elderly are
51 disproportionately affected with severe and symptomatic disease, we hypothesized that a young
52 population might have experienced an epidemic without having recognized it before COVID-19
53 become widely known. Such a prior epidemic might explain slower growth of the epidemic in
54 sub-Saharan Africa than elsewhere. We hypothesized that a severe influenza-like illness was
55 epidemic in Addis Ababa, Ethiopia around the time COVID-19 was recognized, and might
56 represent a prior epidemic. Because responses taken to contain COVID-19 prevent population-
57 based sampling, and due to the urgency of the situation, we undertook a serological study of
58 approximately 100 persons presenting to a laboratory for other reasons, and an additional group
59 convalescent from the outbreak in November 2019/February 2020, to assess the extent of
60 exposure of the population in Addis Ababa and indirectly assess whether this epidemic may have
61 been attributable to SARS CoV-2.

62

63 The study was conducted at International Clinical Laboratories in Addis Ababa, Ethiopia, which
64 offers the Abbott IgG test run on the ARCHITECT platform with approval of the Ethiopian Food
65 and Drug Administration to the general public. This test, which has received the European CE

66 mark and an Emergency Use Authorization from the US Food and Drug Administration, has
67 been found to have 100% sensitivity and 99.9% specificity using the Abbott-determined index
68 value cutoff of 1.4 in an independent study by the University of Washington conducted in Idaho,
69 USA.(3) It has not yet been independently validated in Africa.

70

71 Subjects enrolled as part of the two groups met the following eligibility criteria: Age 14 years or
72 higher; resident in Addis Ababa for all of November 2019-February 2020 and no travel outside
73 Ethiopia since November 1, 2019. The following exclusion criteria also were absent: sore
74 throat, runny nose, cough or difficulty breathing and/or hospitalized or quarantined in the last 28
75 days; measured temperature >99.6 Fahrenheit, resting heart rate >100/minute, and/or resting
76 respiratory rate ≥ 25 /minute); incarceration for a crime; unwilling to participate; or unable to
77 consent. The study was approved in advance by the Institutional Review Boards of MyungSung
78 Medical College (Addis Ababa, Ethiopia) and Partners Healthcare (Boston, USA), and the Addis
79 Ababa Regional Health Bureau; subjects provided written informed consent in Amharic or
80 English.

81

82 After training the study team, 99 subjects were recruited from the participating laboratory's
83 waiting room during May 18-21 inclusive; their characteristics are summarized in the **Table**.
84 Among these, three tested positive for SARS CoV-2 IgG (3.03%, 95% binomial exact
85 confidence interval (CI): 0.63%-8.6%). None of the positive cases were taking medications; one
86 had a chronic runny nose with no other symptoms. Taking into account the sampling scheme
87 and pre-test probability (1.26% based on 1,923 positive results among 152,334 tests as of June 9,
88 2020(4)), the range of plausible values according to the method of Larremore and colleagues(5)

89 are given in the **Figure**. Forty-five Ethiopians recruited from the investigators' network who
90 recalled being sick with a COVID-compatible illness between November 1, 2019 and February
91 29, 2020, were recruited enrolled May 22-27, of whom one tested positive for SARS CoV-2 IgG
92 (2.2%, 95% CI: 0.056%-12%).

93
94 Our results, the first serological general population data on SARS-CoV2 reported from sub-
95 Saharan Africa, are a start toward the vast and important work of characterizing the extent of
96 spread over time in this region with approximately one-seventh of the world's population. While
97 the results of this kind of sample are limited in scope and not easily generalizable, the results do
98 suggest that the large majority of residents of Addis Ababa have not yet been infected by SARS
99 CoV-2 and are at risk. The results do not suggest any particular risk factors for SARS CoV-2
100 seropositivity.

101
102 Decision-makers in Ethiopia, Africa, and elsewhere all are faced with the dilemma of weighing
103 the trade-offs between the direct consequences of the COVID-19 epidemic and the health,
104 economic and other consequences of aggressive control measures.(2) Given the very young age
105 structure of sub-Saharan Africa with associated lesser direct risk from COVID-19,(6, 7) the risk
106 of famine(8) and limited access to essential services(1) as well as economic problems in this
107 region as collateral problems from COVID-19-associated public panic and restrictive policies,
108 different decisions may be appropriate in the African situation than in countries with an older
109 population age structure and developed economic situation. (9)

110

111 **Figure Caption:** The range of plausible values of SARS CoV-2 IgG seropositivity among
112 asymptomatic persons with no history of COVID-19 infection, expressed as probability density
113 (Addis Ababa, Ethiopia, May 2020), based on sensitivity and specificity results for the test
114 determined by the University of Washington(3) is shown in black. An alternative range under
115 less favorable sensitivity and specificity assumptions is given in red. Se=sensitivity;
116 Sp=specificity.

117

118 **Two Sentence Biography of First Author:** Dr. John H. Kempen is Director of Epidemiology
119 for Ophthalmology/Senior Scholar, Massachusetts Eye and Ear/Schepens Eye Research Institute,
120 and Professor of Ophthalmology, Harvard Medical School. He is President of Sight for Souls, a
121 charity developing self-sustaining eye care systems in developing countries, and spends much of
122 the year doing development work, teaching, and research in Addis Ababa, Ethiopia.

123

124

125 **Acknowledgments:** We thank Daniel B. Larremore, PhD and Yonatan Grad, PhD for preparing
126 the Figure in accordance with their method.(5)

127

128 **References:**

- 129 1. Roberton T, Carter ED, Chou VB, Stegmuller AR, Jackson BD, Tam Y, et al. Early
130 estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in
131 low-income and middle-income countries: a modelling study. *The Lancet Global health*. 2020
132 May 12.
- 133 2. Thornton J. Covid-19: Africa's case numbers are rising rapidly, WHO warns. *BMJ*. 2020
134 Jun 15;369:m2394.
- 135 3. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance
136 Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise,
137 Idaho. *J Clin Microbiol*. 2020 May 7.
- 138 4. Tadesse L. Notification Note on COVID-19 Situational Update. Ministry of Health
139 Ethiopia; 2020.
- 140 5. Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, et al.
141 Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from
142 serological surveys. *medRxiv*. 2020:2020.04.15.20067066.
- 143 6. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal
144 COVID-19 cases: A systematic literature review and meta-analysis. *J Infect*. 2020 Apr 23.
- 145 7. Diop BZ, Ngom M, Pougue Biyong C, Pougue Biyong JN. The relatively young and rural
146 population may limit the spread and severity of COVID-19 in Africa: a modelling study. *BMJ*
147 *Glob Health*. 2020 May;5(5).
- 148 8. Mukiibi E. COVID-19 and the state of food security in Africa. *Agric Human Values*.
149 2020 May 14:1-2.

150 9. Mehtar S, Preiser W, Lakhe NA, Bousso A, TamFum JM, Kallay O, et al. Limiting the
 151 spread of COVID-19 in Africa: one size mitigation strategies do not fit all countries. The Lancet
 152 Global health. 2020 Jul;8(7):e881-e3.

153

154 **Table:** Characteristics of subjects who tested negative or positive for
 155 SARS CoV-2 IgG in Addis Ababa, Ethiopia (May, 2020)

	SARS CoV-2 IgG	
	Negative	Positive
Female	55%	67%
Age (years), mean	37.8	33.3
Ethiopian	97%	100%
Total count of people at home, mean	3.8	3.7
Count of children at home, mean	0.97	1.0
Health care worker	19.4%	33.3%
Hypertension	12.9%	0.0%
Diabetes mellitus	12.1%	0.0%
Obesity	4.4%	0.0%
Lung disease	2.2%	0.0%
Pregnant (among females)	9.8%	0.0%
Smoker	3.3%	0.0%
Any symptoms*	24.7%	33.3%
Contact with confirmed COVID-19 case	1.1%	0.0%
Subject thinks (s)he had COVID-19 before**	1.2%	0.0%
Exposure to traveler***	8.6%	0.0%
*Any of the following symptoms each month between November 2019-March 2020 inclusive: fever>37.7 C; feverish (did not measure); chills; headache; coughing or sneezing (more than normal); sore throat; difficulty breathing; runny/stuffy nose; "feeling more tired than usual"; decreased appetite; body or muscle aches; joint pains; decreased sense of smell or taste; nausea; vomiting>2 times; abdominal pain; diarrhea. The subject with positive test result reported a runny/stuffy nose for all five months and no other symptoms.		
**Nine subjects were "not sure," including one with positive test result.		
***Family member, friend or co-worker traveled outside Ethiopia between November 2019-March 2020 inclusive.		

156

